Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion

Basic Research in Cardiology · Published 2026-04-17 · DOI 10.1007/s00395-026-01177-6

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s00395-026-01177-6

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles